Welcome to the CGTA Research Group

Our name stands for “CNS Gene therapy Translation Acceleration.”

Our goal is to bring gene therapies for rare Central Nervous System diseases into clinical trials and use as quickly and efficiently as possible.  Our first project is focused on developing a gene therapy for Huntington’s disease.



April, 2018:

We have successfully re-submitted our grant application to the National Institute of Neurological Diseases and Stroke for work towards a gene therapy for Huntington’s Disease that is complementary to developments that are underway by commercial companies, and which we believe will be useful to them.  Our application will be reviewed by the appropriate study section of the NINDS in June, 2018.

See our news page for more details.